Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) has entered an agreement with Path BioAnalytics (PBA) to evaluate the Recce 327 and Recce 529 therapies against SARS-CoV-2
- PBA will use its respiratory organoid technology to evaluate Recce’s compound therapies against SARS-CoV-2
- The study will be conducted at a leading research university in the U.S.
- Preliminary results are expected in September this year
- Company shares have soared 28.8 per cent and are trading for $1.48 each
Recce Pharmaceuticals (RCE) has entered an agreement with Path BioAnalytics Inc (PBA) for the study of Recce 327 and Recce 529 against SARS-CoV-2.
The study will evaluate both compound therapies to prevent or mitigate SARS-CoV-2 infections.
PBA is a precision medicinal company and is based in North Carolina, U.S. Its primary focus is on using its industry-leading respiratory organoid technology to evaluate SARS-CoV-2 treatments on behalf of companies worldwide.
Its respiratory organoids are pseudo-stratified, 3D cell cultures that come from primary respiratory cells that replicate an airway are responsive to SARS-CoV-2 infection.
PBA researchers will evaluate Recce 327 and Recce 529 against SARS-CoV-2 in an ex vivo respiratory organoid model system.
Recce 327 is a broad-spectrum, synthetic, antibiotic-formulation that treats blood infections and sepsis. Recce 529 is a new synthetic polymer formulation that has been built on Recce’s anti-infective expertise.
“We’re excited to be working with experts at Path BioAnalytics to investigate the potential effectiveness of Recce’s compounds in the treatment of SARS-CoV-2 infection using their advanced respiratory organoid model system,” Non Executive Chairman Dr John Prendergast said.
The study will be conducted in laboratories at a leading research university in the U.S., where the infection of the organoids will take place.
Preliminary data is expected in September this year.
Company shares have soared 28.8 per cent and are trading for $1.48 each at 12:53 pm AEST.
